Cubist Pharmaceuticals is a biopharmaceutical company developing and commercializing medications for acute care in hospitals and surgical environments.
The budding company who increased profits by 14% from 2012 to 2013 is based in Lexington in the US and has over 900 employees; it is currently marketing three major products and has five more in the developmental pipeline. The company has started to acquire companies and continues to build its foundation in the industry so that it can achieve its aim of becoming a leader in the discovery of novel acute care therapies.
The company’s lead product is CUBICIN, an antibiotic which belongs to the class of lipopeptides. CUBICIN actually has an interesting story behind it in that it used be owned by big pharma company Eli Lilly who after several studies discontinued its work on it as a drug candidate. It was then that Cubist bravely in-licensed it and started its own human trials upon it developing it as an i.v. form which after much hard work eventually paid off in 2003 when it became approved for skin infection treatments caused by gram-positive organisms. CUBICIN went from strength to strength thereafter becoming approved in the US for S.aureas bloodstream infections with companies scrambling to market it in other countries.
Cubist also has another key product under its wing, ENTEREG which is an FDA approved therapy that accelerates gastrointestinal recovery following surgery. Most recently Cubist acquired two more infectious disease products through company acquisitions; the first being a late stage product for gram + infections and the second a product called DIFICIN, these have further cemented the company’s position in the infectious disease field and will no doubt flag them as the partner to partner with in this area.
The shape of partnering
Since its beginnings in 1992 Cubist Pharmaceuticals has grown steadily, in 1996 it filed for its initial Public Offering and after then its internal growth began to attract the attention of other companies who wanted to become a partner of or join the companies infrastructure. After only 5 years of operating it signed a huge in-licensing partnership with Eli Lilly and the product of that agreement CUBICIN again placed Cubist on the partnering path as companies wanted to work with the company to market the product around the world.
With its now proven expertise and success in antibiotics, Cubist has become big enough to do some acquiring of its own; in 2013 it purchased two companies Trius Therapeutics and Optimer Therapeutics in 2013 which as well as increasing its capabilities instantly provided with two further products for its pipeline.
Cubist continues to look for novel therapeutics including small molecules, proteins and antibodies at any stage of the research and development process. To these companies Cubist can offer clinical, regulatory and commercial experience. Cubist asks any potential collaborators with potential partnership candidates to provide a non-confidential package of the opportunity together with supporting scientific data directly to it.
Cubist Pharmaceuticals is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Cubist Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Cubist Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting Cubist Pharmaceuticals for partnering
Cubist Pharmaceuticals can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Cubist Pharmaceuticals’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Cubist Pharmaceuticals website has details for contacting Cubist Pharmaceuticals .
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Cubist Pharmaceuticals’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Cubist Pharmaceuticals Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Cubist Pharmaceuticals website for potential partnering opportunities and general contact names.
Cubist Pharmaceuticals partnering at Current Agreements
Full details on each deal can be found at CurrentAgreements (subscription required)
Available reports from Current Partnering
Report: Partnering Agreements with Cubist Pharmaceuticals 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Cubist Pharmaceuticals
Read: more on Cubist Pharmaceuticals company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk